Therapeutic Protein Engineering

Infrastructure Unit

Contact

Esmeralda Woestenenk

Recent user publications

The publications in this database are the result of research conducted at the units of SciLifeLab – both in user projects and technology development.

Population pharmacokinetic modelling of cetirizine concentrations in human breast milk-A contribution from the ConcePTION project.

E. Melander, EI. Nielsen, A. Lindqvist, (…), P. Baranczewski, O. Spigset, H. Nordeng,

Protective Non-neutralizing anti-N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence.

A. Izadi, M. Godzwon, A. Söderlund Strand, (…), C. Drosten, M. Ohlin, P. Nordenfelt,

J. Immunol.213 (5) 678-689

Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries

D. Akaberi, M. Pourghasemi Lati, J. Krambrich, (…), Å. Lundkvist, O. Verho, J. Lennerstrand,

AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine-associated receptor 1.

A. Díaz-Holguín, M. Saarinen, DD. Vo, (…), Y. Yang, J. Carlsson, P. Svenningsson,

Sci Adv10 (32) eadn1524

Personnel

Per-Åke Nygren, Platform Scientific Director
Esmeralda Woestenenk, Head of Unit
Leif Dahllund
Juni Andrell
Ainhoa Moliner-Morro
Oskar Andersson
Pauliina Turunen

SciLifeLab / Services / Our infrastructure / Therapeutic Protein Engineering

Therapeutic Protein Engineering

The Therapeutic Protein Engineering (TPE) unit provides recombinant proteins needed for biochemical screening and therapeutic applications as well as antigens for human antibody production using bacterial and mammalian expression systems. The unit also houses competence and machinery to characterize purified proteins in detail, like binding, stability, and aggregation tendency.

The TPE unit also does phage display selection, characterisation and engineering of antibodies and antibody fragments. This work is shared with our sister unit in Lund: Display & Selection Technologies. More information can be found under that unit.

Services

Delivery of pharmaceutical target proteins for screening and MOA studies including:
- Construct design, cloning and expression analysis
- Expression in E. coli, insect cells, transient and stable pool mammalian cells up to 20L scale
- Purification and biophysical characterisation of proteins
Expression, purification and characterisation of biopharmaceutical candidates for Proof of Concept and MOA studies
qPCR expression analysis
Mammalian cells for screening
Thermal shift screens (DSF)
Support in biochemical screening assay design and setup

Equipment

Watch our cells grow!

Fully equipped lab for protein expression and purification
ambr15 Microbioreactor
Light Cycler 480 II
Isothermal calorimeter
Biacore 8K
Liquid handling robot
Prometheus NT.48 with Backreflection Optics
Malvern DLS
Refeyn Mass Photometer TwoMP